

Provided for non-commercial research and education use.  
Not for reproduction, distribution or commercial use.



This is an open access article which appeared in a journal published by Elsevier. This article is free for everyone to access, download and read.

Any restrictions on use, including any restrictions on further reproduction and distribution, selling or licensing copies, or posting to personal, institutional or third party websites are defined by the user license specified on the article.

For more information regarding Elsevier's open access licenses please visit:

<http://www.elsevier.com/openaccesslicenses>

## EDITORIAL COMMENT

## MicroRNA-24 and the Diabetic Heart\*



Marieke Rienks, MD, PhD, Abhishek Joshi, BA, MChB, MD, Manuel Mayr, MD, PhD

Patients with diabetes are at risk of vascular complications, leading to cardiovascular, renal, and neurological disease. In this issue of *JACC: Basic to Translational Science*, Wang et al. (1) suggest that impaired infarct healing in diabetics results from a hyperinsulinemia- and hyperglycemia-induced down-regulation of microribonucleic acid (microRNA, miRNA)-24 (miR-24). The authors ascribe the protective effect of miR-24 to repression of protein targets involved in apoptosis, autophagy, and protein O-GlcNAcylation. Raising miR-24 is proposed as a potential therapeutic approach for improving post-infarct healing in patients with type 2 diabetes (T2D).

SEE PAGE 350

In contrast with the absence of a preventative benefit of intense glucose control in a primary prevention setting (2), incident acute myocardial infarction (MI) in diabetic patients is associated with increased subsequent heart failure and mortality (3), both during initial hospitalization and long-term follow-up. However, early enthusiasm for intensive insulin treatment has given way to an agnostic

approach, as large studies found benefits and potential harm associated with these strategies (4). The higher mortality and complication rates in T2D patients are multifactorial and probably related to the duration of glycemic dysregulation. Why do T2D patients treated with insulin fail to show an improved clinical outcome?

Wang et al. (1) suggest that insulin therapy, added to higher baseline insulin levels reduces miR-24 levels, with adverse effects after ischemic injury. According to the authors, this may, at least in part, explain the lack of therapeutic efficacy of insulin treatment in T2D patients post-MI.


A strength of this study is the use of 2 murine models, one akin to T2D and type 1 diabetes (T1D). Although insulin use increased mortality post-MI in db/db mice (T2D), insulin use decreased mortality in mice treated with streptozotocin (T1D). Wang et al. demonstrate a reduction in infarct size after ischemia reperfusion in db/db mice after systemic administration of nanoparticles containing miR-24 as well as in transgenic mice that have cardiomyocyte-specific overexpression of miR-24. O-GlcNAc transferase, Bcl-2-like protein 11, and autophagy-related 4A cysteine peptidase are the proposed targets of miR-24 responsible (Figure 1). Similar to most miRNAs, miR-24 is ubiquitously expressed (5). Qian et al. (6) have previously shown that in vivo administration of miR-24 nanoparticles inhibited cardiomyocyte apoptosis in a mouse model of MI, thereby attenuating infarct size and reducing cardiac dysfunction by directly acting on Bcl-2-like protein 11.

MiR-24 is also part of a pri-miR cluster, together with miR-23 and miR-27 (7). Increased expression of miR-24 but also of miR-27b has been associated with cardiac dysfunction (8,9). Previously, the authors reported that hyperglycemia represses miR-24 in endothelial cells. Reduced miR-24 was associated with increased von Willebrand factor secretion by endothelial cells (10). Notably, Fiedler et al. (11)

\*Editorials published in *JACC: Basic to Translational Science* reflect the views of the authors and do not necessarily represent the views of *JACC: Basic to Translational Science* or the American College of Cardiology.

From the King's British Heart Foundation Centre, King's College London, London, United Kingdom. Dr. Joshi is a British Heart Foundation (BHF) Clinical Research training fellow (FS/16/32/32184). Dr. Mayr is a BHF Chair Holder (CH/16/3/32406) with BHF program grant support (RG/16/14/32397) and member of a network on "MicroRNA-based Therapeutic Strategies in Vascular Disease" funded by the Fondation Leducq; and he is named as an inventor on patents related to microRNA biomarkers in cardiometabolic disease. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the *JACC: Basic to Translational Science* [author instructions page](#).

**FIGURE 1** MiR-24 and the Diabetic Heart

The infarct size after ischemia-reperfusion is reduced in a mouse model of type 2 diabetes upon microribonucleic acid 24 (miR-24) overexpression. O-GlcNAc transferase (OGT), Bcl-2-like protein 11 (BIM), and autophagy-related 4A cysteine peptidase (ATG4A) are proposed as targets of miR-24. Insulin treatment reduced mortality in a mouse model of type 1 diabetes, but not type 2 diabetes. The observed plasma changes in miR-24 may not be connected to myocardial tissue.

revealed that miR-24 is up-regulated after MI and enriched in cardiac endothelial cells under normoglycemia. Blocking endothelial miR-24 using antagonists limited infarct size by preventing endothelial cell apoptosis and enhancing vascularity (6). Thus, miR-24 appears to affect both endothelial cells and cardiomyocytes, with opposite outcomes in post-MI remodeling.

Wang et al. further demonstrate a decrease in miR-24 in response to hyperinsulinemia in a clamp study in 5 T1D patients. A significant decrease in miR-24 levels was observed in the plasma of T2D compared with T1D patients. We have recently identified miR-24 as an abundant miRNA in platelets. Its plasma levels are reduced by antiplatelet therapy (12). Diabetics are known to have increased platelet reactivity (13). Reduced platelet miRNAs, including miR-24, were among the predominant changes in circulating miRNAs in patients with T2D (14,15). Insulin antagonizes platelet activation, but platelets from T2D are less sensitive to this effect due to their insulin resistance (15). Therefore, differential miR-24 detection in the plasma of T2D may reflect differential platelet reactivity,

especially as the plasma isolation protocol in Wang et al. does not prevent pre-analytic platelet activation (16). The rapid reduction of plasma miR-24 seen in Wang et al.'s glucose clamp experiment supports this suggestion; as insulin levels increase, platelet reactivity is reduced and platelet "poor" plasma subsequently demonstrates reduced miR-24 levels (17).

Although it would be an oversimplification to attribute myocardial dysfunction after MI in T2D to the dysregulation of an individual miRNA such as miR-24, the study by Wang et al. emphasizes the significance of miR-24 in the ischemic diabetic heart (Figure 1). Also, the proposed role for circulating miRNAs such as miR-24 in the pathophysiology of infarct healing in diabetics in relation to insulin sensitivity and production as demonstrated by this study encourages further exploration.

**ADDRESS FOR CORRESPONDENCE:** Dr. Manuel Mayr, King's British Heart Foundation Centre, King's College London, 125 Coldharbour Lane, London SE5 9NU, United Kingdom. E-mail: [manuel.mayr@kcl.ac.uk](mailto:manuel.mayr@kcl.ac.uk).

## REFERENCES

- Wang D, Hu X, Lee SH, et al. Diabetes exacerbates myocardial ischemia/reperfusion injury by down-regulation of microRNA and up-regulation of O-GlcNAcylation. *J Am Coll Cardiol Basic Trans Science* 2018;3:350-62.
- Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000;321:405-12.
- Ertl G, Frantz S. Healing after myocardial infarction. *Cardiovasc Res* 2005;66:22-32.
- Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. *Eur Heart J* 2005;26:650-61.
- Barwari T, Joshi A, Mayr M. MicroRNAs in cardiovascular disease. *J Am Coll Cardiol* 2016;68:2577-84.
- Qian L, Van Laake LW, Huang Y, Liu S, Wendland MF, Srivastava D. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. *J Exp Med* 2011;208:549-60.
- Li RC, Tao J, Guo YB, et al. In vivo suppression of microRNA-24 prevents the transition toward decompensated hypertrophy in aortic-constricted mice. *Circ Res* 2013;112:601-5.

8. Xu M, Wu HD, Li RC, et al. Mir-24 regulates junctophilin-2 expression in cardiomyocytes. *Circ Res* 2012;111:837-41.
9. Wang J, Song Y, Zhang Y, et al. Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice. *Cell Res* 2012;22:516-27.
10. Xiang Y, Cheng J, Wang D, et al. Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. *Blood* 2015;125:3377-87.
11. Fiedler J, Jazbutyte V, Kirchmaier BC, et al. MicroRNA-24 regulates vascularity after myocardial infarction. *Circulation* 2011;124:720-30.
12. Willeit P, Zampetaki A, Dudek K, et al. Circulating microRNAs as novel biomarkers for platelet activation. *Circ Res* 2013;112:595-600.
13. Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. *Am J Cardiol* 2003;92:1362-5.
14. Kaudewitz D, Skroblin P, Bender LH, et al. Association of MicroRNAs and YRNAs with platelet function. *Circ Res* 2016;118:420-32.
15. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. *Circ Res* 2010;107:810-7.
16. Randriamboavonjy V, Fleming I. Insulin, insulin resistance, and platelet signaling in diabetes. *Diabetes Care* 2009;32:528-30.
17. Sunderland N, Skroblin P, Barwari T, et al. MicroRNA biomarkers and platelet reactivity: the clot thickens. *Circ Res* 2017;120:418-35.

---

**KEY WORDS** diabetes, microRNAs, myocardial infarction